Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.
Atopic dermatitis is a chronic, inflammatory disease characterized by eczematous skin lesions and intense itch, however, the inflammatory processes underlying AD reach far beyond the skin. Cumulative comorbidities, including other atopic diseases as well as bone and mental health conditions, may result from uncontrolled chronic disease and inflammation both within and beyond the skin in pediatric patients with AD. Development of these extracutaneous health conditions, which may persist into adulthood, can have variable trajectories and contribute to the cumulative life impact of AD.
Join experts Eulàlia Baselga, Amy Paller, and Lisa Weibel as they investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD. The speakers will discuss the potential benefits of treating children with AD early in the disease process and the emerging clinical and real-world data on the use of advanced systemic treatments for children with AD.
Welcome, Objectives, and Audience Polling
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
Early Intervention and the Potential for Disease Modification in Children With AD
Emerging Data on Advanced Systemic Treatments for Children With AD
Conclusions and Live Q&A
The speakers are being compensated and/or receiving honoraria from Sanofi and Regeneron in connection with this program.